Sarcopenia: epidemiology, challenges and opportunities for multidisciplinary practice [title heading]

Harnish P Patel

Pippa Collins

Rachel Everett

Cyrus Cooper

Elaine M Dennison

1 MRC Lifecourse Epidemiology Unit

2 Medicine for Older People, University Hospital Southampton, Southampton, UK 3 Academic Geriatric Medicine, University of Southampton 4 NIHR Biomedical Research Centre, Southampton University of Southampton, Southampton UK.

|  |  |  |  |
| --- | --- | --- | --- |
| Author | Qualifications | Email | Information |
| Harnish P Patel | BSc PhD FRCP | hp@mrc.soton.ac.uk | Corresponding author |
| Pippa Collins | BSc MRes MCSP | Pippa.Collins@uhs.nhs.uk | Senior Clinical Physiotherapist and Advanced Clinical Practitioner in Frailty |
| Rachel Everett | RGN MSc | Rachel.Everett@uhs.nhs.uk | Senior Sister, Advanced Clinical Practitioner in Frailty |
| Cyrus Cooper | OBE DL FMedSci | cc@mrc.soton.ac.uk | Director and Professor of Rheumatology |
| Elaine M Dennison | MA MSc PhD FRCP | emd@mrc.soton.ac.uk | Professor of Musculoskeletal Epidemiology, Honorary Consultant Rheumatologist |

|  |
| --- |
| Address for Correspondence: |
| Dr Harnish Patel  Consultant physician, Geriatric Medicine & Honorary Clinical Senior Lecturer  MRC Lifecourse Epidemiology Unit, University of Southampton Mail point 95, Southampton SO16 6YD, UK  Tel: +44 (0)23 8077 7624, Fax: +44 (0)23 8070 4021 |

Abstract

Sarcopenia, the loss of skeletal muscle mass, strength and function with age, is widely recognised as a major clinical problem for older people that is associated with serious health consequences in terms of frailty, disability, morbidity and mortality, as well as high health care costs. Recent algorithms have provided a systematic approach to case-finding. This article reviews the epidemiology and pathogenesis of sarcopenia and presents an overview of comprehensive geriatric assessment (CGA) as a multidisciplinary-based approach to the assessment, management and follow up of the older patient.

Introduction

Demographic transformations across the world dictate that survival to older age is anticipated to be the norm for all of today’s younger population (Chatterji et al., 2015). Whilst this is a cause for celebration, these cumulative demographic changes pose significant challenges for delivering health and social care to older people.

Sarcopenia is a particularly deleterious expression of ageing that impacts on individuals across a range of health and social care settings, as well as on the consequent health economy (Fuggle et al., 2017, Janssen et al., 2004) . Sarcopenia is characterised by generalised and progressive loss of muscle mass, reduction in muscle strength and resultant functional impairment. The condition is associated with poor health outcomes from disability, morbidity, e.g. diabetes, osteoporosis and consequent frailty (Gale et al., 2007, Sayer et al., 2005, Sayer et al., 2007, Ferrucci et al., 2014, Morley et al., 2014). It is also predictive of mortality not only in older people, but also those who are middle aged (Cooper et al., 2010, Studenski et al., 2011). In 2016, sarcopenia was assigned an official disease classification based on the International Classification of Disease (ICD-10). This reflects the importance of recognizing and managing this condition (Cao and Morley, 2016).

*Skeletal muscle across the life course*

Skeletal muscle comprises 40-60% of total body mass, and plays an essential role in both physical and metabolic functioning, e.g. locomotion, thermoregulation, metabolism of glucose and amino acids (Sender et al., 2016). Muscle is also a reservoir for proteins and energy that can be utilised in periods of stress or undernutrition, such as in any acute deterioration in health and/or hospitalisation.

Muscle development in humans begins at six weeks gestation and continues until approximately 24 weeks at which point the total number of Type I and Type II fibres is set. Any subsequent increase in muscle bulk occurs by hypertrophy (Maltin et al., 2001, Brown, 2014). Muscle mass increases during childhood and adolescence, remains relatively constant in early adulthood, and then is estimated to decline at 8% per decade after the age of 40, up to 70 years, followed by a more precipitous loss of 15% per decade thereafter (Janssen, 2011). Loss of strength appears to be of a higher magnitude with a reported 10-15% loss of leg strength up to 70 years, followed by a greater decline of 25%-40% per decade thereafter (Goodpaster et al., 2006, Grimby and Saltin, 1983, Hughes et al., 2001). In this regard, direct proportionality between loss of muscle mass and impaired strength/function cannot be inferred as evidence from longitudinal, as well as cross-sectional studies show that younger individuals can be weaker, and older in­dividuals stronger, than would be predicted by their muscle mass alone (Kallman et al., 1990, Newman A and al, 2006). Consequently, the health of skeletal muscle in an older person is not only a result of the peak levels they may have attained in mass during their early to mid-life years, but also the extrinsic and intrinsic changes that affect muscle quality, the force generated per unit of muscle area i.e. patterns of physical activity, nutrition, disease, disuse and hormonal changes that may have taken place during their middle years into old age.

*Defining sarcopenia*

Accepted definitions of sarcopenia in research, as well as in clinical practice include loss of muscle mass, strength and physical performance, collectively referred to as function (Cruz-Jentoft et al., 2010). Diagnostic algorithms include those proposed by the European Working Group on Sarcopenia in Older People (EWGSOP) (Cruz-Jentoft et al., 2010), The Foundation for the National Health Institutes of Health (FNIH) Sarcopenia Project (Studenski et al., 2014), and the Asian Working Group for Sarcopenia (AWGS) (Chen et al., 2014).

The EWGSOP definition is most commonly used within the UK and Europe (figure 1). It incorporates slower walk speed (≤0.8m/s), or weaker strength (grip <30kg for men, <20kg for women) in combination with low muscle mass (defined as appendicular lean mass normalised by the square of body height [ALM/ht2] ≤7.23 kg/m2 for men and ≤5.67 kg/m2 for women). From a clinical point of view, this and other algorithms facilitate sarcopenia case-finding, and can conceptually identify stages of sarcopenia that may allow early detection and intervention. For example, and as illustrated in figure 1, the **pre-sarcopenia** stage is characteristic of low muscle mass without impact on muscle strength or physical performance, the **sarcopenia** stage is characterised by low muscle mass, plus low muscle strength or poorer physical performance whilst **severe sarcopenia** is when all three criteria within the algorithm are met (Cruz-Jentoft et al., 2010)**.**

*Measuring muscle mass*

The most common approach in measuring muscle mass is through portable bioimpedance scanning (BIA) and, where available, dual energy x-ray absorptiometry (DXA) scanning. Computerised tomography (CT) and magnetic resonance imaging (MRI) can also be used (Cooper et al., 2012) but high operational costs and radiation in the case of CT, limits their use. Anthropometric measures such as skin fold thickness are prone to error, especially in hospitalised older people and are not suitable for assessing muscle mass in this population.

*Measuring muscle strength*

Hand held dynamometry has gained wide acceptance, across healthcare settings, as a reliable and valid measure of muscle strength (Roberts et al., 2011, Roberts et al., 2012). Other methods include ascertainment of knee extensor power, isometric knee strength and quadriceps torque, but these require static and bulky equipment that can be impractical for use in routine practice.

*Measuring physical performance*

Slower gait speed is associated with risk of future morbidity and mortality, and is therefore suitable for inclusion in diagnostic algorithms for sarcopenia (Vermeulen et al., 2011). Measurement of gait speed requires intact coordination, and neural and joint control so may not be practical in context of acutely unwell, hospitalised older people. In this situation, grip strength measurements may have better predictive value and be more feasible (Roberts et al., 2012, Ibrahim et al., 2018).

*Prevalence of sarcopenia*

Whilst it is clear that sarcopenia increases with age, estimates of its prevalence vary widely in different clinical settings, reflecting divergence in the approaches used for its definition, the ethnicity of the population studied, and the cut-off values for lean mass and function. In their systematic review Cruz-Jentoft *et al* (2014) reported rates of between 1 and 29% in community-dwelling populations and of 14–33% in long-term care residents. In the UK, the prevalence of sarcopenia, using the EWGSOP definition in the Hertfordshire Cohort Study was 4.6% in men and 7.9 % in women, mean age of 67 years, (Patel et al., 2013).

*Questionnaires to aid the diagnosis of sarcopenia*

The SARC-F questionnaire was developed to predict poor muscle function (Malmstrom and Morley, 2013, Cao et al., 2014) and is based on five questions that ascertain how much difficulty an individual has in performing the following parameters:

* ability to rise from a chair
* walk assisted or unassisted
* climb stairs
* carry heavy loads (as a measure of strength).

It also contains an ascertainment on the number of falls a person has had over the previous 12-month period.

Each parameter is assigned a score: none (0); some (1); or a lot (2); the falls parameter score is none (0), 1-3 (1), 4 or more (2). A total score of ≥4 on a scale of 0-10 suggests that the subject is symptomatic of sarcopenia. While the SARC-F questionnaire has been shown to have excellent specificity, it has poor sensitivity for sarcopenia and so may be useful for case identification and subsequent diagnostic evaluation in a community-based setting rather than in hospital or care home based settings (Woo et al., 2014), and therefore could be of practical value to therapists working in the community.

Despite the recent progress in refining and implementing criteria, at present no global consensus exists regarding the diagnostic criteria for sarcopenia based on cut off values for skeletal muscle mass indices, grip strength and walking speed. However, ongoing collaborative efforts by the EWGSOP, FNIH and AWGSOP aim to harmonise the definition of sarcopenia for research and clinical use worldwide.

Pragmatic indicators of whether an individual is at risk of sarcopenia can be useful for the multi-discipline team (MDT), both in the hospital setting and within the community, and these can trigger a referral for more specialist assessment (Fielding et al., 2011, Morley et al., 2011):

|  |
| --- |
| * Measured gait speed < 1.0 m/s measured over a 6m course |
| * Post-hospitalisation as a consequence of disuse and deconditioning |
| * Recent weight loss |
| * Reduced levels of physical activity |
| * History of recurrent falls |
| * Self-reported functional difficulty, e.g. inability to get out of a bed or rise from a chair independently |
| * Decline in overall health |
| * Recent weight loss |
| * Presence of co-existent, comorbid conditions, e.g. Type 2 diabetes, heart failure, COPD |

Conditions such as malnutrition and cachexia can lead to muscle wasting and there can be considerable overlap in these entities with sarcopenia that can be difficult to disentangle, especially in hospitalised older people (Patel, 2014). However, clues from the patient’s history and examination can point to the predominant cause. Starvation leads to a loss on non-fat structures, as well as body fat, whilst cachexia is associated with severe muscle wasting as well as loss of body fat that is driven by a marked pro-inflammatory state, e.g. cancer or heart failure. Body fat in individuals with sarcopenia is often preserved or increased and while individuals with cachexia can be sarcopenic, individuals with sarcopenia are not considered cachectic (Malafarina et al., 2012).

*Pathogenesis of sarcopenia*

Multiple intracellular cell signaling pathways execute environmental and cellular cues that determine myofibre size through protein synthesis or degradation. These include the insulin like growth factor -1 (IGF-I) signaling pathways that promote protein synthesis,and pathways associated with protein catabolism that are mediated by inflammatory mediators, e.g. tumour necrosis factor alpha (TNF) and interleukin 6 (IL-6), among others (Goodman et al., 2011). While the acute inflammatory response can be beneficial to promote muscle repair and regeneration, the persisting, chronic, and low grade production of inflammatory cytokines that appear to be present in older individuals can adversely impact on muscle mass and function and there is substantial evidence linking inflammation with sarcopenia (Beyer *et al* 2012).

Skeletal muscle ageing is also characterised by a continuous cycle of denervation and reinnervation, as a consequence of the loss of alpha-motor neurones within the central nervous system (CNS). Withdrawal of nerve terminals from the neuromuscular junctions (NMJ) and axonal sprouting from neighbouring neurons collectively give rise to larger, inefficient motor units. Remodeling skeletal muscle tissue through neuropathic, neurohormonal and inflammatory pathways leads to a reduction in muscle cross sectional area, volume and a reduced rate of force generation (Hepple and Rice, 2016). This is characterised by the presence of fewer Type I oxidative (slow twitch) and Type II glycolytic (fast twitch) myofibres, myofibre atrophy and concurrent increase in non-contractile material.

**Challenges and opportunities for multidisciplinary practice**

Sarcopenia is considered a core component of frailty, indicating loss of physiological reserve in the skeletal muscle system (Landi et al., 2015). However, in the typical phenotype of frailty, the gradual decline in physiological reserves is accelerated and accumulates across multiple systems, including the brain, immune, endocrine, cardiorespiratory, renal and haematological systems, as well as skeletal muscle. This accelerated decline across multiple systems can lead to failure of homeostatic mechanisms which, in turn leads to vulnerability to adverse outcomes following minor stressor events. There is strong evidence that individuals living with frailty have poorer outcomes and die sooner than expected (Clegg et al., 2016, Clegg et al., 2013). As weakness tends to be the first sign of frailty and given that slow walking speed and low physical activity typically precede weight loss and exhaustion, identification of sarcopenia may be an especially useful method of recognising those people at increased risk of progression in their frailty status.

Interventions for individuals living with sarcopenia

*Nutrition*

The synthesis of muscle fibres requires adequate protein. Physiological changes in the gastrointestinal system is associated with a blunted anabolic response to ingested proteins (Robinson et al., 2012). As such, older people may require more protein to counteract the inflammatory and catabolic effects not only associated with the sarcopenic phenotype, but also with co-existent co-morbidities and their exacerbations (Wandrag et al., 2015). Protein supplements vary in their composition and current evidence from trials is inconsistent to enable the development of evidence-based recommendations for protein supplementation in sarcopenia (Hickson, 2015, Beaudart et al., 2017). However, observational evidence does suggest that essential amino acids, i.e. leucine and beta-hydroxy-beta-methylbutyrate (a bioactive metabolite of leucine), stimulates muscle protein synthesis more than non-essential amino acids and may be useful for maintaining lean body mass and improving muscle function (Deutz et al., 2013, Paddon-Jones et al., 2004, Wu et al., 2015, Flakoll et al., 2004, Stout et al., 2013). A recent consensus statement from the multinational PROT-AGE group recommend that older people have a protein intake of at least 1.2-1.5 grams per body weight (kg) per day to maintain muscle homeostatsis (Bauer et al., 2013). Low vitamin D levels are also associated with decreased muscle strength and vitamin D supplement, especially for those older individuals who are deficient, may have positive effects on muscle strength (Beaudart et al., 2014). Ultimately, however, whole diet modifications rather than single agent supplementation may be more appropriate strategies when advising dietary changes in older people (Hickson, 2015). At present there are no medicine based treatments for sarcopenia.

*Physical activity*

Physical inactivity and sedentary behaviour are common among older people, and this can lead to an acceleration in muscle catabolism as well as reduced aerobic capacity. In conjunction with other personal, social and environmental factors, such as issues with access to food and social isolation, a decline in physical activity can create a spiral of further inactivity, muscle loss, weight gain, mobility problems and an increase in cardio-metabolic risk (Ford and Caspersen, 2012, Ryan et al., 2015).

Combining physical activity and nutritional interventions can be associated with better function, strength and less inflammation in older sarcopenic people (Rondanelli et al., 2016, Churchward-Venne et al., 2013, Naseeb and Volpe, 2017). In terms of physical activity, progressive resistance and aerobic exercise have been shown to be the most beneficial for the prevention and ‘treatment’ of sarcopenia (Cruz-Jentoft et al., 2014, Liu and Latham, 2009, Pahor et al., 2014, Valenzuela, 2012). Whilst progressive resistance exercise improves lean mass, strength and function (Peterson et al., 2011), optimising exercise capacity through aerobic activity improves metabolic control, reduces oxidative stress, insulin sensitivity and can stimulate a hypertrophic response on muscle fibres. Despite being shown to be safe and effective in older people (Fiatarone et al., 1994, Liu and Latham, 2009, Vincent et al., 2002), implementing progressive exercise in clinical practice is not always readily achievable. However, recent evidence suggests even incremental elevations in habitual activity in older people may help decelerate age related declines in musculoskeletal fitness (Westbury et al., 2018).

Falls are a serious, and sometimes can be a fatal complication of sarcopenia. A multicomponent approach that addresses balance and gait, flexibility and endurance, and lower limb strengthening is required to manage those susceptible to falls. These approaches are aimed at improving reaction time, gait, balance, strength coordination and physical and cognitive function (El-Khoury et al., 2013, Stubbs et al., 2015). Group and home based exercise programmes, which incorporate safety interventions, may reduce the rate and risk of falling (Robertson and Gillespie, 2013), moreover, targeted home-based or group-based exercise interventions can also improve mobility and functional outcomes for older people (Clegg et al., 2012, Theou et al., 2011).

Intervening earlier in the life course, before or at the onset of mild functional limitation, may have huge benefits for later skeletal muscle health. For example, Dodds *et al* (2013) ascertained that increased levels of leisure time physical activity in mid-life was associated with stronger grip strength in both men and women at age 60-64. This is consistent with optimising peak strength earlier on in life, thereby reducing the impact of sarcopenia. Regular physical activity in adulthood may, therefore prevent a more precipitous decline in muscle strength in older age (Dodds et al., 2013).

Hospitalisation of older individuals is commonly associated with immobility and bed confinement, with a typical length of stay in hospital of between 7-10 days (Lim et al., 2018). Studies have shown that during prolonged bedrest there is an immediate and significant reduction in muscle protein synthesis, loss of muscle mass, strength/function, and aerobic capacity. (Coker et al., 2015, Kortebein et al., 2008). Rapid Identification of these individuals and implementing interventions to maintain muscle function between periods of bed-rest should be a priority for the MDT and may provide opportunities for innovative ways of maintaining physical activity levels.

*Comprehensive Care planning*

It is clear that the older person’s care requirements are complex and that they often have co-existent functional, psychological and social needs. Ultimately, the treatment goals for an older person with sarcopenia revolve around improving physical function and maintaining independence and well-being. A useful method for planning the care of those living with sarcopenia and frailty is through a process of CGA, a multi-professional diagnostic process that involves medical, nursing, therapy, dietetics, and social services, etc. It is focused on determining the psychological and functional capability of the older person in order to develop a coordinated, integrated and personalised care plan for treatment, and long term follow up (Ellis et al., 2011). With the patient at the centre of their decision-making process, the purpose of CGA is to improve diagnostic accuracy, optimise treatment and minimise polypharmacy. Additionally, the aim is to improve outcomes and crucially, allow effective integrated case management that ensures that the care plan is enacted and remains continually responsive to the patient’s needs**.** This involves effective communication between secondary and primary care and *vice versa*.The personalised care plan, both diagnostic and therapeutic, can be overseen by any member of the MDT**.** There is good evidence that CGA, when delivered to patients in both the community and within the hospital setting, is associated with decreased mortality, the likelihood of the patient experiencing better function and cognition rather than a deterioration in health and / or being institutionalised (Ellis et al., 2011, Stuck et al., 2002, Cameron et al., 2013). Equally, the CGA process can facilitate appropriate advanced care planning discussions with individuals who may be towards the end of their life.

Summary

Sarcopenia is a major health problem for older people. Clearly, early identification as well as a better understanding of mechanisms underpinning the development of sarcopenia will create a basis for clinical trials and therapeutic interventions. Physical activity and nutrition are currently the cornerstones of interventions as currently no drug is licenced for the treatment of sarcopenia.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

BAUER, J., BIOLO, G., CEDERHOLM, T., CESARI, M., CRUZ-JENTOFT, A. J., MORLEY, J. E., PHILLIPS, S., SIEBER, C., STEHLE, P., TETA, D., VISVANATHAN, R., VOLPI, E. & BOIRIE, Y. 2013. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. *J Am Med Dir Assoc,* 14**,** 542-59.

BEAUDART, C., BUCKINX, F., RABENDA, V., GILLAIN, S., CAVALIER, E., SLOMIAN, J., PETERMANS, J., REGINSTER, J. Y. & BRUYERE, O. 2014. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab,* 99**,** 4336-45.

BEAUDART, C., DAWSON, A., SHAW, S. C., HARVEY, N. C., KANIS, J. A., BINKLEY, N., REGINSTER, J. Y., CHAPURLAT, R., CHAN, D. C., BRUYERE, O., RIZZOLI, R., COOPER, C. & DENNISON, E. M. 2017. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. *Osteoporos Int,* 28**,** 1817-1833.

BROWN, L. D. 2014. Endocrine regulation of fetal skeletal muscle growth: impact on future metabolic health. *J Endocrinol,* 221**,** R13-29.

CAMERON, I. D., FAIRHALL, N., LANGRON, C., LOCKWOOD, K., MONAGHAN, N., AGGAR, C., SHERRINGTON, C., LORD, S. R. & KURRLE, S. E. 2013. A multifactorial interdisciplinary intervention reduces frailty in older people: randomized trial. *BMC Med,* 11**,** 65.

CAO, L., CHEN, S., ZOU, C., DING, X., GAO, L., LIAO, Z., LIU, G., MALMSTROM, T. K., MORLEY, J. E., FLAHERTY, J. H., AN, Y. & DONG, B. 2014. A pilot study of the SARC-F scale on screening sarcopenia and physical disability in the Chinese older people. *J Nutr Health Aging,* 18**,** 277-83.

CAO, L. & MORLEY, J. E. 2016. Sarcopenia Is Recognized as an Independent Condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code. *J Am Med Dir Assoc,* 17**,** 675-7.

CHATTERJI, S., BYLES, J., CUTLER, D., SEEMAN, T. & VERDES, E. 2015. Health, functioning, and disability in older adults--present status and future implications. *Lancet,* 385**,** 563-75.

CHEN, L. K., LIU, L. K., WOO, J., ASSANTACHAI, P., AUYEUNG, T. W., BAHYAH, K. S., CHOU, M. Y., CHEN, L. Y., HSU, P. S., KRAIRIT, O., LEE, J. S., LEE, W. J., LEE, Y., LIANG, C. K., LIMPAWATTANA, P., LIN, C. S., PENG, L. N., SATAKE, S., SUZUKI, T., WON, C. W., WU, C. H., WU, S. N., ZHANG, T., ZENG, P., AKISHITA, M. & ARAI, H. 2014. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc,* 15**,** 95-101.

CHURCHWARD-VENNE, T. A., MURPHY, C. H., LONGLAND, T. M. & PHILLIPS, S. M. 2013. Role of protein and amino acids in promoting lean mass accretion with resistance exercise and attenuating lean mass loss during energy deficit in humans. *Amino Acids,* 45**,** 231-40.

CLEGG, A., BARBER, S., YOUNG, J., FORSTER, A. & ILIFFE, S. 2012. Do home-based exercise interventions improve outcomes for frail older people? Findings from a systematic review. *Reviews in clinical gerontology,* 22**,** 68-78.

CLEGG, A., BATES, C., YOUNG, J., RYAN, R., NICHOLS, L., ANN TEALE, E., MOHAMMED, M. A., PARRY, J. & MARSHALL, T. 2016. Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing,* 45**,** 353-60.

CLEGG, A., YOUNG, J., ILIFFE, S., RIKKERT, M. O. & ROCKWOOD, K. 2013. Frailty in elderly people. *Lancet,* 381**,** 752-62.

COKER, R. H., HAYS, N. P., WILLIAMS, R. H., WOLFE, R. R. & EVANS, W. J. 2015. Bed rest promotes reductions in walking speed, functional parameters, and aerobic fitness in older, healthy adults. *J Gerontol A Biol Sci Med Sci,* 70**,** 91-6.

COOPER, C., DERE, W., EVANS, W., KANIS, J. A., RIZZOLI, R., SAYER, A. A., SIEBER, C. C., KAUFMAN, J. M., ABELLAN VAN KAN, G., BOONEN, S., ADACHI, J., MITLAK, B., TSOUDEROS, Y., ROLLAND, Y. & REGINSTER, J. Y. 2012. Frailty and sarcopenia: definitions and outcome parameters. *Osteoporos Int,* 23**,** 1839-48.

COOPER, R., KUH, D. & HARDY, R. 2010. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. *Bmj,* 341**,** c4467.

CRUZ-JENTOFT, A. J., BAEYENS, J. P., BAUER, J. M., BOIRIE, Y., CEDERHOLM, T., LANDI, F., MARTIN, F. C., MICHEL, J. P., ROLLAND, Y., SCHNEIDER, S. M., TOPINKOVA, E., VANDEWOUDE, M. & ZAMBONI, M. 2010. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing.,* 39**,** 412-423.

CRUZ-JENTOFT, A. J., LANDI, F., SCHNEIDER, S. M., ZUNIGA, C., ARAI, H., BOIRIE, Y., CHEN, L. K., FIELDING, R. A., MARTIN, F. C., MICHEL, J. P., SIEBER, C., STOUT, J. R., STUDENSKI, S. A., VELLAS, B., WOO, J., ZAMBONI, M. & CEDERHOLM, T. 2014. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Ageing,* 43**,** 748-59.

DEUTZ, N. E., PEREIRA, S. L., HAYS, N. P., OLIVER, J. S., EDENS, N. K., EVANS, C. M. & WOLFE, R. R. 2013. Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. *Clin Nutr,* 32**,** 704-12.

DODDS, R., KUH, D., AIHIE SAYER, A. & COOPER, R. 2013. Physical activity levels across adult life and grip strength in early old age: updating findings from a British birth cohort. *Age Ageing,* 42**,** 794-8.

EL-KHOURY, F., CASSOU, B., CHARLES, M. A. & DARGENT-MOLINA, P. 2013. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. *Bmj,* 347**,** f6234.

ELLIS, G., WHITEHEAD, M. A., O'NEILL, D., LANGHORNE, P. & ROBINSON, D. 2011. Comprehensive geriatric assessment for older adults admitted to hospital. *Cochrane Database Syst Rev***,** Cd006211.

FERRUCCI, L., BARONI, M., RANCHELLI, A., LAURETANI, F., MAGGIO, M., MECOCCI, P. & RUGGIERO, C. 2014. Interaction between bone and muscle in older persons with mobility limitations. *Curr Pharm Des,* 20**,** 3178-97.

FIATARONE, M. A., O'NEILL, E. F., RYAN, N. D., CLEMENTS, K. M., SOLARES, G. R., NELSON, M. E., ROBERTS, S. B., KEHAYIAS, J. J., LIPSITZ, L. A. & EVANS, W. J. 1994. Exercise training and nutritional supplementation for physical frailty in very elderly people. *N.Engl.J Med.,* 330**,** 1769-1775.

FIELDING, R. A., VELLAS, B., EVANS, W. J., BHASIN, S., MORLEY, J. E., NEWMAN, A. B., ABELLAN VAN KAN, G., ANDRIEU, S., BAUER, J., BREUILLE, D., CEDERHOLM, T., CHANDLER, J., DE MEYNARD, C., DONINI, L., HARRIS, T., KANNT, A., KEIME GUIBERT, F., ONDER, G., PAPANICOLAOU, D., ROLLAND, Y., ROOKS, D., SIEBER, C., SOUHAMI, E., VERLAAN, S. & ZAMBONI, M. 2011. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc,* 12**,** 249-56.

FLAKOLL, P., SHARP, R., BAIER, S., LEVENHAGEN, D., CARR, C. & NISSEN, S. 2004. Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women. *Nutrition,* 20**,** 445-51.

FORD, E. S. & CASPERSEN, C. J. 2012. Sedentary behaviour and cardiovascular disease: a review of prospective studies. *Int J Epidemiol,* 41**,** 1338-53.

FUGGLE, N., SHAW, S., DENNISON, E. & COOPER, C. 2017. Sarcopenia. *Best Pract Res Clin Rheumatol,* 31**,** 218-242.

GALE, C. R., MARTYN, C. N., COOPER, C. & SAYER, A. A. 2007. Grip strength, body composition, and mortality. *Int J Epidemiol,* 36.

GOODMAN, C. A., MAYHEW, D. L. & HORNBERGER, T. A. 2011. Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. *Cell Signal.*

GOODPASTER, B. H., PARK, S. W., HARRIS, T. B., KRITCHEVSKY, S. B., NEVITT, M., SCHWARTZ, A. V., SIMONSICK, E. M., TYLAVSKY, F. A., VISSER, M. & NEWMAN, A. B. 2006. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. *J Gerontol A Biol.Sci.Med Sci.,* 61**,** 1059-1064.

GRIMBY, G. & SALTIN, B. 1983. The ageing muscle. *Clin Physiol,* 3**,** 209-18.

HEPPLE, R. T. & RICE, C. L. 2016. Innervation and neuromuscular control in ageing skeletal muscle. *J Physiol,* 594**,** 1965-78.

HICKSON, M. 2015. Nutritional interventions in sarcopenia: a critical review. *Proc Nutr Soc,* 74**,** 378-86.

HUGHES, V. A., FRONTERA, W. R., WOOD, M., EVANS, W. J., DALLAL, G. E., ROUBENOFF, R. & FIATARONE SINGH, M. A. 2001. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. *J Gerontol A Biol Sci Med Sci,* 56**,** B209-17.

IBRAHIM, K., MAY, C. R., PATEL, H. P., BAXTER, M., SAYER, A. A. & ROBERTS, H. C. 2018. Implementation of grip strength measurement in medicine for older people wards as part of routine admission assessment: identifying facilitators and barriers using a theory-led intervention. *BMC Geriatr,* 18**,** 79.

JANSSEN, I. 2011. The epidemiology of sarcopenia. *Clin Geriatr Med,* 27**,** 355-63.

JANSSEN, I., SHEPARD, D. S., KATZMARZYK, P. T. & ROUBENOFF, R. 2004. The healthcare costs of sarcopenia in the United States. *J Am Geriatr.Soc,* 52**,** 80-85.

KALLMAN, D. A., PLATO, C. C. & TOBIN, J. D. 1990. The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. *J Gerontol,* 45**,** M82-M88.

KORTEBEIN, P., SYMONS, T. B., FERRANDO, A., PADDON-JONES, D., RONSEN, O., PROTAS, E., CONGER, S., LOMBEIDA, J., WOLFE, R. & EVANS, W. J. 2008. Functional impact of 10 days of bed rest in healthy older adults. *J Gerontol A Biol Sci Med Sci,* 63**,** 1076-81.

LANDI, F., CALVANI, R., CESARI, M., TOSATO, M., MARTONE, A. M., BERNABEI, R., ONDER, G. & MARZETTI, E. 2015. Sarcopenia as the Biological Substrate of Physical Frailty. *Clin Geriatr Med,* 31**,** 367-74.

LIM, S. E. R., DODDS, R., BACON, D., SAYER, A. A. & ROBERTS, H. C. 2018. Physical activity among hospitalised older people: insights from upper and lower limb accelerometry. *Aging Clin Exp Res*.

LIU, C. J. & LATHAM, N. K. 2009. Progressive resistance strength training for improving physical function in older adults. *Cochrane.Database.Syst.Rev.***,** CD002759.

MALAFARINA, V., URIZ-OTANO, F., INIESTA, R. & GIL-GUERRERO, L. 2012. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. *Maturitas,* 71**,** 109-14.

MALMSTROM, T. K. & MORLEY, J. E. 2013. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. *J Am Med Dir Assoc,* 14**,** 531-2.

MALTIN, C. A., DELDAY, M. I., SINCLAIR, K. D., STEVEN, J. & SNEDDON, A. A. 2001. Impact of manipulations of myogenesis in utero on the performance of adult skeletal muscle. *Reproduction.,* 122**,** 359-374.

MORLEY, J. E., ABBATECOLA, A. M., ARGILES, J. M., BARACOS, V., BAUER, J., BHASIN, S., CEDERHOLM, T., COATS, A. J., CUMMINGS, S. R., EVANS, W. J., FEARON, K., FERRUCCI, L., FIELDING, R. A., GURALNIK, J. M., HARRIS, T. B., INUI, A., KALANTAR-ZADEH, K., KIRWAN, B. A., MANTOVANI, G., MUSCARITOLI, M., NEWMAN, A. B., ROSSI-FANELLI, F., ROSANO, G. M., ROUBENOFF, R., SCHAMBELAN, M., SOKOL, G. H., STORER, T. W., VELLAS, B., VON, H. S., YEH, S. S. & ANKER, S. D. 2011. Sarcopenia with limited mobility: an international consensus. *J Am.Med Dir.Assoc.,* 12**,** 403-409.

MORLEY, J. E., MALMSTROM, T. K., RODRIGUEZ-MANAS, L. & SINCLAIR, A. J. 2014. Frailty, sarcopenia and diabetes. *J Am Med Dir Assoc,* 15**,** 853-9.

NASEEB, M. A. & VOLPE, S. L. 2017. Protein and exercise in the prevention of sarcopenia and aging. *Nutr Res,* 40**,** 1-20.

NEWMAN A, B. & AL, E. 2006. Strength, but not muscle mass is associated with mortality in the health aging and body composition study cohort. *J Gerontol:Med Sci,* 61A**,** 72-77.

PADDON-JONES, D., SHEFFIELD-MOORE, M., ZHANG, X. J., VOLPI, E., WOLF, S. E., AARSLAND, A., FERRANDO, A. A. & WOLFE, R. R. 2004. Amino acid ingestion improves muscle protein synthesis in the young and elderly. *Am.J Physiol Endocrinol.Metab,* 286**,** E321-E328.

PAHOR, M., GURALNIK, J. M., AMBROSIUS, W. T., BLAIR, S., BONDS, D. E., CHURCH, T. S., ESPELAND, M. A., FIELDING, R. A., GILL, T. M., GROESSL, E. J., KING, A. C., KRITCHEVSKY, S. B., MANINI, T. M., MCDERMOTT, M. M., MILLER, M. E., NEWMAN, A. B., REJESKI, W. J., SINK, K. M. & WILLIAMSON, J. D. 2014. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. *Jama,* 311**,** 2387-96.

PATEL, H. P. 2014. Sarcopenia: A condition in need for identification in different health care settings. *Rev Clin Esp,* 214**,** 313-4.

PATEL, H. P., SYDDALL, H. E., JAMESON, K., ROBINSON, S., DENISON, H., ROBERTS, H. C., EDWARDS, M., DENNISON, E., COOPER, C. & AIHIE SAYER, A. 2013. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). *Age Ageing,* 42**,** 378-84.

PETERSON, M. D., SEN, A. & GORDON, P. M. 2011. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. *Med Sci Sports Exerc,* 43**,** 249-58.

ROBERTS, H. C., DENISON, H. J., MARTIN, H. J., PATEL, H. P., SYDDALL, H., COOPER, C. & SAYER, A. A. 2011. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing.,* 40**,** 423-429.

ROBERTS, H. C., SYDDALL, H. E., COOPER, C. & AIHIE SAYER, A. 2012. Is grip strength associated with length of stay in hospitalised older patients admitted for rehabilitation? Findings from the Southampton grip strength study. *Age Ageing,* 41**,** 641-6.

ROBERTSON, M. C. & GILLESPIE, L. D. 2013. Fall prevention in community-dwelling older adults. *Jama,* 309**,** 1406-7.

ROBINSON, S., COOPER, C. & AIHIE, S. A. 2012. Nutrition and sarcopenia: a review of the evidence and implications for preventive strategies. *J Aging Res.,* 2012:510801. Epub;%2012 Mar 15.**,** 510801.

RONDANELLI, M., KLERSY, C., TERRACOL, G., TALLURI, J., MAUGERI, R., GUIDO, D., FALIVA, M. A., SOLERTE, B. S., FIORAVANTI, M., LUKASKI, H. & PERNA, S. 2016. Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. *Am J Clin Nutr,* 103**,** 830-40.

RYAN, D. J., STEBBINGS, G. K. & ONAMBELE, G. L. 2015. The emergence of sedentary behaviour physiology and its effects on the cardiometabolic profile in young and older adults. *Age (Dordr),* 37**,** 89.

SAYER, A. A., DENNISON, E. M., SYDDALL, H. E., GILBODY, H. J., PHILLIPS, D. I. & COOPER, C. 2005. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? *Diabetes Care,* 28**,** 2541-2542.

SAYER, A. A., SYDDALL, H. E., DENNISON, E. M., MARTIN, H. J., PHILLIPS, D. I., COOPER, C. & BYRNE, C. D. 2007. Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. *QJM.,* 100**,** 707-713.

SENDER, R., FUCHS, S. & MILO, R. 2016. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol,* 14**,** e1002533.

STOUT, J. R., SMITH-RYAN, A. E., FUKUDA, D. H., KENDALL, K. L., MOON, J. R., HOFFMAN, J. R., WILSON, J. M., OLIVER, J. S. & MUSTAD, V. A. 2013. Effect of calcium beta-hydroxy-beta-methylbutyrate (CaHMB) with and without resistance training in men and women 65+yrs: a randomized, double-blind pilot trial. *Exp Gerontol,* 48**,** 1303-10.

STUBBS, B., BREFKA, S. & DENKINGER, M. D. 2015. What Works to Prevent Falls in Community-Dwelling Older Adults? Umbrella Review of Meta-analyses of Randomized Controlled Trials. *Phys Ther,* 95**,** 1095-110.

STUCK, A. E., EGGER, M., HAMMER, A., MINDER, C. E. & BECK, J. C. 2002. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. *Jama,* 287**,** 1022-8.

STUDENSKI, S., PERERA, S., PATEL, K., ROSANO, C., FAULKNER, K., INZITARI, M., BRACH, J., CHANDLER, J., CAWTHON, P., CONNOR, E. B., NEVITT, M., VISSER, M., KRITCHEVSKY, S., BADINELLI, S., HARRIS, T., NEWMAN, A. B., CAULEY, J., FERRUCCI, L. & GURALNIK, J. 2011. Gait speed and survival in older adults. *Jama,* 305**,** 50-8.

STUDENSKI, S. A., PETERS, K. W., ALLEY, D. E., CAWTHON, P. M., MCLEAN, R. R., HARRIS, T. B., FERRUCCI, L., GURALNIK, J. M., FRAGALA, M. S., KENNY, A. M., KIEL, D. P., KRITCHEVSKY, S. B., SHARDELL, M. D., DAM, T. T. & VASSILEVA, M. T. 2014. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci,* 69**,** 547-58.

THEOU, O., STATHOKOSTAS, L., ROLAND, K. P., JAKOBI, J. M., PATTERSON, C., VANDERVOORT, A. A. & JONES, G. R. 2011. The effectiveness of exercise interventions for the management of frailty: a systematic review. *J Aging Res,* 2011**,** 569194.

VALENZUELA, T. 2012. Efficacy of progressive resistance training interventions in older adults in nursing homes: a systematic review. *J Am Med Dir Assoc,* 13**,** 418-28.

VERMEULEN, J., NEYENS, J. C., VAN ROSSUM, E., SPREEUWENBERG, M. D. & DE WITTE, L. P. 2011. Predicting ADL disability in community-dwelling elderly people using physical frailty indicators: a systematic review. *BMC Geriatr,* 11**,** 33.

VINCENT, K. R., BRAITH, R. W., FELDMAN, R. A., MAGYARI, P. M., CUTLER, R. B., PERSIN, S. A., LENNON, S. L., GABR, A. H. & LOWENTHAL, D. T. 2002. Resistance exercise and physical performance in adults aged 60 to 83. *J Am Geriatr.Soc.,* 50**,** 1100-1107.

WANDRAG, L., BRETT, S. J., FROST, G. & HICKSON, M. 2015. Impact of supplementation with amino acids or their metabolites on muscle wasting in patients with critical illness or other muscle wasting illness: a systematic review. *J Hum Nutr Diet,* 28**,** 313-30.

WESTBURY, L. D., DODDS, R. M., SYDDALL, H. E., BACZYNSKA, A. M., SHAW, S. C., DENNISON, E. M., ROBERTS, H. C., SAYER, A. A., COOPER, C. & PATEL, H. P. 2018. Associations Between Objectively Measured Physical Activity, Body Composition and Sarcopenia: Findings from the Hertfordshire Sarcopenia Study (HSS). *Calcif Tissue Int*.

WOO, J., LEUNG, J. & MORLEY, J. E. 2014. Validating the SARC-F: a suitable community screening tool for sarcopenia? *J Am Med Dir Assoc,* 15**,** 630-4.

WU, H., XIA, Y., JIANG, J., DU, H., GUO, X., LIU, X., LI, C., HUANG, G. & NIU, K. 2015. Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: a systematic review and meta-analysis. *Arch Gerontol Geriatr,* 61**,** 168-75.




Figure 1. The European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic algorithm for sarcopenia case finding adapted from (Cruz-Jentoft et al., 2010).